ViatrisVTRSEarnings & Financial Report
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
VTRS Q3 2025 Key Financial Metrics
売上高
$3.7B
粗利益
$1.4B
営業利益
$178.8M
純利益
N/A
粗利益率
36.6%
営業利益率
4.8%
純利益率
N/A
前年比成長
0.3%
EPS
$-0.11
資金フロー
Viatris Q3 2025 Financial Summary
Viatris reported revenue of $3.7B for Q3 2025, with a net profit of N/A (N/A margin). Cost of goods sold was $2.4B, operating expenses totaled $1.2B.
Key Financial Metrics
| Total Revenue | $3.7B |
|---|---|
| Net Profit | N/A |
| Gross Margin | 36.6% |
| Operating Margin | 4.8% |
| Report Period | Q3 2025 |
Viatris Annual Revenue by Year
Viatris annual revenue history includes year-by-year totals (for example, 2024 revenue was $14.7B).
| Year | Annual Revenue |
|---|---|
| 2024 | $14.7B |
| 2023 | $15.4B |
| 2022 | $16.2B |
損益計算書
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $3.83B | $3.65B | $3.79B | $3.74B | $3.52B | $3.24B | $3.57B | $3.75B |
| 前年比成長 | -1.1% | -1.8% | -3.2% | -5.0% | -8.1% | -11.2% | -5.7% | 0.3% |
貸借対照表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $47.69B | $47.34B | $45.33B | $44.75B | $41.50B | $38.47B | $38.41B | $37.92B |
| 総負債 | $27.22B | $27.33B | $25.81B | $24.96B | $22.87B | $22.82B | $22.84B | $22.70B |
| 株主資本 | $20.47B | $20.01B | $19.52B | $19.79B | $18.64B | $15.65B | $15.57B | $15.22B |
キャッシュフロー
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $479.4M | $614.6M | $379.1M | $826.5M | $482.7M | $535.5M | $219.7M | $744.9M |
Other Health Care Companies
BMY
Bristol Myers Squibb
売上高
$12.5B
純利益
$1.1B
JNJ
Johnson & Johnson
売上高
$24.6B
純利益
$5.1B
LLY
Lilly (Eli)
売上高
$19.3B
純利益
$6.6B
MRK
Merck & Co.
売上高
$17.3B
純利益
$5.8B
PFE
Pfizer
売上高
$16.7B
純利益
$3.5B
ZTS
Zoetis
売上高
$2.4B
純利益
$603.0M
ABT
Abbott Laboratories
売上高
$11.4B
純利益
$1.6B
ABBV
AbbVie
売上高
$15.8B
純利益
$186.0M
A
Agilent Technologies
売上高
$1.9B
純利益
$434.0M
ALGN
Align Technology
売上高
$995.7M
純利益
$56.8M